Elsevier

Journal of the Neurological Sciences

Volume 372, 15 January 2017, Pages 331-341
Journal of the Neurological Sciences

Review Article
Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

https://doi.org/10.1016/j.jns.2016.11.067Get rights and content

Highlights

  • Data of a large number MS patients showed high prevalence of depression and anxiety.

  • Prevalence of depressive or anxiety symptoms was elevated compared with disorders.

  • Prevalence rates varied considerably between included studies

  • It is important to agree on patient recruitment and definition of depression/anxiety.

  • To improve prevalence estimates we should focus on specific patient characteristics.

Abstract

Objective

Prevalence rates of depression and anxiety in patients with Multiple Sclerosis (MS) vary widely across studies. Aim of this systematic review and meta-analysis was to a) estimate the prevalence of depression and anxiety in MS, and specifically b) explore sources of heterogeneity (assessment method, prevalence period, study quality, recruitment resource, region) by extensive analyses.

Methods

A computerized search in PubMed, EMBASE, and PsycINFO for studies on depression and anxiety in MS was performed up to December 2014.

Results

Fifty-eight articles with a total sample size of 87,756 MS patients were selected. Pooled mean prevalence was 30.5% (95% CI = 26.3%–35.1%) for depression, and 22.1% (95% CI = 15.2%–31.0%) for anxiety. Prevalence of clinically significant depressive or anxiety symptoms was higher (35% and 34%) compared with disorders (21%; p = 0.001 and 10%; p < 0.001). Prevalence of a depressive disorder was relatively lower in studies from Europe. Anxiety disorder was more prevalent in community-based samples. Sources of high heterogeneity were not revealed.

Conclusions

Data of a large number of patients indicate increased prevalence of depression and anxiety in MS. Further research is needed to identify sources of heterogeneity. Issues to consider are the definition of depression and anxiety, patient recruitment, and patient characteristics.

Introduction

Depression and anxiety are common in Multiple Sclerosis (MS) and elevated compared with the general population [1]. Explanations for comorbidity are multifactorial and concern a complex interplay of variables. Depression and anxiety could be natural reactions to the unpredictable course of a disabling and chronic disease. Further, MS patients could be predisposed for depression or anxiety by several psychosocial risk factors such as inadequate coping or insufficient social support, or by MS-related biological processes such as changes in brain structure or in immunological and inflammatory pathways [2], [3], [4], [5]. In reverse, depression and anxiety may adversely affect health status by increasing symptom burden, negatively influencing adherence to treatment regimens or by direct pathophysiological effects on immunity [6], [7]. Depression and anxiety in MS patients are related to lower quality of life, cognitive dysfunction, elevated suicide risk, and working problems [4], [8]. Since depression and anxiety in MS seem to worsen over time and as they are often treatable, early recognition is important and knowledge on their presence and management should be further improved in order to enhance clinical care [4], [9], [10], [11].

The increased risk of depression or anxiety in MS has often been reported but prevalence rates vary widely from 14% up to 54% [9], [12]. This variation could be due to a number of methodological issues, such as differences in definitions, instruments and diagnostic criteria used, and size and nature of the population studied [13]. Often the terms ‘depression’ and ‘anxiety’ refer to clinically significant symptoms revealed by self-report scales of different quality, which makes it difficult to compare findings [9], [14]. Besides, these scales cannot be used to establish a formal diagnosis of psychiatric disorders and tend to overestimate prevalence rates as compared with diagnostic interviews [13], [15]. Further, depressive and anxiety symptomatology in MS has frequently been studied in small MS samples attending MS-clinics or in inpatient settings, underrepresenting patients who are coping well in the community [1], [16], [17].

A systematic review pooling data from population-based studies showed that depression and anxiety both affect > 20% of the MS population [14]. Although the authors performed sensitivity analyses and focused on high quality studies, a high degree of heterogeneity was observed. This implied that prevalence rates varied considerably between the included studies, hampering solid conclusions for the MS population. It is therefore clearly of interest to determine the causes of this heterogeneity as is also suggested by the Cochrane Handbook [18]. This has, to the best of our knowledge, not been previously performed. In addition to revealing the sources of heterogeneity and improving prevalence estimates, it might also offer explanations for the elevated prevalence rates in MS.

In this systematic review and meta-analysis, we therefore aimed to provide a targeted analysis of studies on the prevalence of depression and anxiety in MS and 1) estimate the prevalence of depression and anxiety in MS, and in addition 2) explore sources of heterogeneity by performing subgroup analyses. We evaluated whether the average prevalence estimates varied in relation to a) different definitions of depression and anxiety (disorder vs clinically significant symptoms); b) various methods of assessment and prevalence period; c) quality of research papers; d) patient recruitment resources; and e) different regions. By exploring the heterogeneity by conducting subgroup analyses, we strived to obtain a more comprehensive view on the prevalence of depression and anxiety in MS and its implications for future research.

Section snippets

Search strategy

A systematic computerized search in PubMed, EMBASE, and Psycinfo was completed in December 2014 for studies on depression and anxiety in Multiple Sclerosis. In collaboration with the librarian, a search strategy was developed which was adjusted correspondingly for each of the databases: The medical subject headings (MeSH) terms ‘Depression’, ‘Depressive Disorder’, ‘Depressive’, ‘Anxiety’, ‘Anxiety Disorders’, ‘Anxious’, ‘Emotions’, ‘Affective Symptoms’, ‘Mood Disorders’, ‘Distress’,

Results

The literature search identified 2999 articles published between August 1965 and December 2014. Examination of titles and abstracts resulted in 112 publications that were considered for inclusion. After full-text assessment, 58 articles met the inclusion criteria and were included in this review with a total sample size of 87,756 MS patients [11], [17], [28], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61],

Discussion

Aim of this systematic review and meta-analysis was to estimate the prevalence of depression and anxiety in MS, and specifically to explore sources of heterogeneity by extensive analyses. This review elaborated on previous reviews on depression and anxiety in MS [1], [12], [14]. It included a large sample with > 87.000 MS patients and investigated 23 studies that were not considered previously [14]. We demonstrated consistent evidence of high prevalence rates of depression (31%) and anxiety

Conflicts of interest and source of funding

There are no conflicts of interests for all authors. This work was supported by the Stichting MS Research (Grant number 09-678).

Acknowledgements

We would like to express our thanks and acknowledge the help of Caroline Planting in the development of our search strategy.

References (120)

  • M.G. Carta et al.

    The risk of bipolar disorders in multiple sclerosis

    J. Affect. Disord.

    (2014)
  • A.M. da Silva et al.

    Depression and anxiety in a Portuguese MS population: associations with physical disability and severity of disease

    J. Neurol. Sci.

    (2011)
  • K. van der Hiele et al.

    Daily hassles reported by Dutch multiple sclerosis patients

    J. Neurol. Sci.

    (2012)
  • M.P. Jensen et al.

    Social support, depression, and physical disability: age and diagnostic group effects

    Disabil. Health J.

    (2014)
  • J. Nuyen et al.

    Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study

    J. Clin. Epidemiol.

    (2006)
  • S.B. Patten et al.

    Clinical correlates of CES-D depressive symptom ratings in an MS population

    Gen. Hosp. Psychiatry

    (2005)
  • S. Pittion-Vouyovitch et al.

    Fatigue in multiple sclerosis is related to disability, depression and quality of life

    J. Neurol. Sci.

    (2006)
  • R. Viner et al.

    Point prevalence and correlates of depression in a national community sample with multiple sclerosis

    Gen. Hosp. Psychiatry

    (2014)
  • B. Löwe et al.

    Measuring depression outcome with a brief self-report instrument: sensitivity to change of the patient health questionnaire (PHQ-9)

    J. Affect. Disord.

    (2004)
  • R.C. Kessler

    The costs of depression

    Psychiatr. Clin. N. Am.

    (2012)
  • A. Feinstein et al.

    The link between multiple sclerosis and depression

    Nat. Rev. Neurol.

    (2014)
  • A. Feinstein

    Multiple sclerosis and depression

    Mult. Scler.

    (2011)
  • Goldman Consensus Group

    The Goldman consensus statement on depression in multiple sclerosis

    Mult. Scler.

    (2005)
  • A. Feinstein et al.

    Structural brain abnormalities in multiple sclerosis patients with major depression

    Neurology

    (2004)
  • D.C. Mohr et al.

    Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

    Arch. Neurol.

    (1997)
  • S. Fruehwald et al.

    Depression and quality of life in multiple sclerosis

    Acta Neurol. Scand.

    (2001)
  • S.L. Minden et al.

    Guideline development Subcommittee of the American Academy of neurology, evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the guideline development Subcommittee of the American Academy of neurology

    Neurology

    (2014)
  • D. Hind et al.

    Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis

    BMC Psychiatry.

    (2014)
  • M.W. Koch et al.

    Depression in multiple sclerosis: a long-term longitudinal study

    Mult. Scler.

    (2015)
  • R.J. Siegert et al.

    Depression in multiple sclerosis: a review

    J. Neurol. Neurosurg. Psychiatry

    (2005)
  • S.B. Patten et al.

    Depression in multiple sclerosis

    Psychother. Psychosom.

    (1997)
  • R.A. Marrie et al.

    The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review

    Mult. Scler.

    (2015)
  • F. Creed et al.

    Depression in the medically ill

  • S.B. Patten et al.

    Major depression in multiple sclerosis: a population-based perspective

    Neurology

    (2003)
  • Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The...
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

    (1994)
  • World Health Organization

    The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research

    (1993)
  • World Health Organization

    International Classification of Primary Care

    (2011)
  • R.A. Marrie et al.

    Smoking status over two years in patients with multiple sclerosis

    Neuroepidemiology

    (2009)
  • K. Cetin et al.

    Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample

    Mult. Scler.

    (2007)
  • D.C. Mohr et al.

    Treatment of depression for patients with multiple sclerosis in neurology clinics

    Mult. Scler.

    (2006)
  • C. McGuigan et al.

    Unrecognised symptoms of depression in a community-based population with multiple sclerosis

    J. Neurol.

    (2006)
  • C.H. Bombardier et al.

    Alcohol and drug abuse among persons with multiple sclerosis

    Mult. Scler.

    (2004)
  • D.M. Ehde et al.

    Chronic pain in a large community sample of persons with multiple sclerosis

    Mult. Scler.

    (2003)
  • R.J. Buchanan et al.

    Analyses of the minimum data set: comparisons of nursing home residents with multiple sclerosis to other nursing home residents

    Mult. Scler.

    (2002)
  • L. Chwastiak et al.

    Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample

    Am. J. Psychiatry

    (2002)
  • R.A. Marrie et al.

    CIHR team in the epidemiology and impact of comorbidity on multiple sclerosis, performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia

    Chronic Dis. Inj. Can.

    (2014)
  • L. Ostacoli et al.

    Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis

    J. Clin. Psychol. Med. Settings

    (2013)
  • J.P.T. Higgins et al.

    Measuring inconsistency in meta-analyses

    BMJ

    (2003)
  • M. Borenstein et al.

    Introduction to Meta-Analysis

    (2009)
  • Cited by (0)

    View full text